TY - JOUR
T1 - Biomedical application of chitosan-based nanoscale delivery systems
T2 - Potential usefulness in siRNA delivery for cancer therapy
AU - Ashrafizadeh, Milad
AU - Delfi, Masoud
AU - Hashemi, Farid
AU - Zabolian, Amirhossein
AU - Saleki, Hossein
AU - Bagherian, Morteza
AU - Azami, Negar
AU - Farahani, Mahdi Vasheghani
AU - Sharifzadeh, Seyed Omid
AU - Hamzehlou, Soodeh
AU - Hushmandi, Kiavash
AU - Makvandi, Pooyan
AU - Zarrabi, Ali
AU - Hamblin, Michael R.
AU - Varma, Rajender S.
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/5/15
Y1 - 2021/5/15
N2 - Gene therapy is an emerging and promising strategy in cancer therapy where small interfering RNA (siRNA) system has been deployed for down-regulation of targeted gene and subsequent inhibition in cancer progression; some issues with siRNA, however, linger namely, its off-targeting property and degradation by enzymes. Nanoparticles can be applied for the encapsulation of siRNA thus enhancing its efficacy in gene silencing where chitosan (CS), a linear alkaline polysaccharide derived from chitin, with superb properties such as biodegradability, biocompatibility, stability and solubility, can play a vital role. Herein, the potential of CS nanoparticles has been discussed for the delivery of siRNA in cancer therapy; proliferation, metastasis and chemoresistance are suppressed by siRNA-loaded CS nanoparticles, especially the usage of pH-sensitive CS nanoparticles. CS nanoparticles can provide a platform for the co-delivery of siRNA and anti-tumor agents with their enhanced stability via chemical modifications. As pre-clinical experiments are in agreement with potential of CS-based nanoparticles for siRNA delivery, and these carriers possess biocompatibiliy and are safe, further studies can focus on evaluating their utilization in cancer patients.
AB - Gene therapy is an emerging and promising strategy in cancer therapy where small interfering RNA (siRNA) system has been deployed for down-regulation of targeted gene and subsequent inhibition in cancer progression; some issues with siRNA, however, linger namely, its off-targeting property and degradation by enzymes. Nanoparticles can be applied for the encapsulation of siRNA thus enhancing its efficacy in gene silencing where chitosan (CS), a linear alkaline polysaccharide derived from chitin, with superb properties such as biodegradability, biocompatibility, stability and solubility, can play a vital role. Herein, the potential of CS nanoparticles has been discussed for the delivery of siRNA in cancer therapy; proliferation, metastasis and chemoresistance are suppressed by siRNA-loaded CS nanoparticles, especially the usage of pH-sensitive CS nanoparticles. CS nanoparticles can provide a platform for the co-delivery of siRNA and anti-tumor agents with their enhanced stability via chemical modifications. As pre-clinical experiments are in agreement with potential of CS-based nanoparticles for siRNA delivery, and these carriers possess biocompatibiliy and are safe, further studies can focus on evaluating their utilization in cancer patients.
KW - Cancer therapy
KW - Chitosan
KW - Gene delivery
KW - Nanoparticle
KW - Small interfering RNA (siRNA)
UR - http://www.scopus.com/inward/record.url?scp=85101591856&partnerID=8YFLogxK
U2 - 10.1016/j.carbpol.2021.117809
DO - 10.1016/j.carbpol.2021.117809
M3 - Review article
C2 - 33712155
AN - SCOPUS:85101591856
SN - 0144-8617
VL - 260
JO - Carbohydrate Polymers
JF - Carbohydrate Polymers
M1 - 117809
ER -
